Cigarettes, vapes, alcohol: What lifestyle habits disqualify you from donating blood?
While public campaigns often focus on increasing donations, what is less often discussed is this: not everyone is eligible to give and sometimes, lifestyle choices, however casual, can lead to permanent deferrals.
'The first and most important point to emphasise is that blood donation operates on a two-way responsibility.
'While it is crucial to encourage people to come forward, it is equally vital that the donors themselves are healthy,' SJMC Consultant Haematologist, Dr Ng Soo Chin told Sinar Daily.
SJMC Consultant Haematologist, Dr Ng Soo Chin.
And in the eyes of healthcare professionals, 'healthy' is not just about looking and feeling well, it also means being free of risky behaviours that might silently endanger recipients.
Among the strictest disqualifiers for blood donation are high-risk behaviours, particularly involving recreational drug use. This includes marijuana, injected drugs or experimentation with unknown substances.
'Individuals with high-risk behaviours such as consuming marijuana or experimenting with other drugs, fall into a category where the risk of undetectable infections like HIV cannot be completely ruled out.
'Even with state-of-the-art screening technology that reduces the HIV 'window period' to less than a week, there remains a small chance of missing an early infection.
'Therefore, for safety reasons, individuals with such drug use history may be deferred, especially if the drug was injected intravenously, which would disqualify them from donating for life,' Dr Ng explained.
What matters most, he added, is honesty during the pre-donation interview. The reliability of a donor's history during pre-donation interviews is one of the most crucial factors in maintaining a safe blood supply.
Photo for illustrative purposes only. Photo: Canva
Interestingly, not all lifestyle choices automatically disqualify someone. Smoking and vaping, for instance, do not necessarily prevent a person from donating, provided they have stopped at least a week prior.
'Smoking or vaping are generally considered acceptable if discontinued at least a week before donating. As for alcohol? Moderation is key.
'Moderate alcohol consumption is also permissible, but donors are encouraged to wait at least 24 hours before donating to ensure safety,' he added.
Today, SJMC remains one of the few private hospitals still licensed to operate its own in-house blood bank.
'Many hospital-based blood banks have been phased out due to stringent standards imposed by the National Blood Transfusion Centre.
'Regular inspections are conducted and institutions that fail to meet the required benchmarks risk having their licence withdrawn. Fortunately, we have maintained our compliance and continue to serve the public.
'The scope of operations has expanded considerably. We are not just looking to fill bags, we are ensuring every unit of blood is as safe as it is life-saving,' he added.
And while donors are often motivated by altruism, Dr Ng reminds us that eligibility is not about judgement, it is about protection.
'This is a life-or-death matter. It is our duty to ensure the safety of every patient who receives a transfusion,' he stressed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
12 hours ago
- The Star
Teen pregnancies still an issue in Sabah due to poor sex education, says state assistant minister
KOTA KINABALU: Teenage pregnancies and early marriages remain Sabah's main social challenges due to cultural pressure, poverty and lack of sex education. Sabah community development and people's wellbeing assistant minister Datuk Flovia Ng said this issue, if not addressed, would perpetuate the cycle of poverty and educational attrition in Sabah. "This would affect the development of our youth," she said when officiating the Sabah Population Seminar in conjunction with the World Population Day here on Thursday (July 31). She said the increase in unplanned pregnancies and emotional stress amongst young mothers needs targeted intervention initiatives, comprehensive reproductive health education and easy access to inclusive counselling services. Ng said integrated programmes such as those on child marriages are vital to create awareness in the community while educating parents and children. She added that the socio-economic gap between urban and rural folk was still apparent, with many facing numerous issues such as lack of basic infrastructure, education, healthcare and job opportunities.
Malay Mail
2 days ago
- Malay Mail
From crisis to collaboration: Why harm reduction is Malaysia's public health opportunity — Bakhtiar Talhah
JULY 31 — Almost two decades ago, I stood at the frontlines of Malaysia's HIV epidemic — a time when fear, stigma and silence ruled the discourse around drug use and HIV. The data was grim: some 70 per cent of new HIV infections were among people who inject drugs (PWIDs). We were losing lives, and our response was fragmented at best. We knew something had to change. What followed was bold and unprecedented. With the support of allies across the Ministry of Health, civil society, law enforcement and religious leadership, we launched the Needle and Syringe Exchange Programme (NSEP) in 2006. At the time, it was politically unpopular. Critics worried it would condone drug use. But we persisted, because science and humanity demanded it. Today, the success is undeniable: HIV transmission among PWIDs and their partners has dropped dramatically. The NSEP saved lives — and transformed mindsets. Yet despite this progress, the underlying policy framework that criminalises and marginalises people who use drugs remains largely intact. Malaysia's drug laws continue to emphasise punishment over rehabilitation, incarceration over care. We cannot meaningfully implement harm reduction while treating drug dependence as a moral failing or criminal offence. This is the core argument: drug policy reform is not just complementary to harm reduction — it is foundational to it. Without reforming our approach to drugs — legally, institutionally, and socially — our harm reduction efforts will always be constrained. We need a national paradigm shift from punitive drug control to public health-based policies. This means decriminalising personal drug use, investing in treatment and prevention services, and empowering community-led initiatives. Other countries have taken this step — and seen measurable public health and economic benefits. Portugal, for instance, decriminalised all drugs in 2001, and instead focused on harm reduction, treatment, and reintegration. As a result, drug-related deaths and HIV infections plummeted. Malaysia must take inspiration and adapt such evidence-based models to our context. And reform doesn't stop with laws. It requires strong political will, inter-agency collaboration, and courage to lead with compassion. When we launched NSEP, success was only possible because of multisectoral alignment — from the Ministry of Health to the Royal Malaysian Police, from NGOs to the Malaysian Islamic Development Department (JAKIM). This is the same spirit we must reignite for wider drug policy reform. Regulation, too, is essential. Harm reduction does not mean lack of control — it demands smart, risk-proportionate governance. Whether it's opioid substitution therapy or access to safer nicotine products, clear and evidence-based regulation ensures both public safety and access to lifesaving tools. This applies directly to Malaysia's fast-evolving tobacco and vape landscape. Overregulation can drive people to unregulated markets; underregulation risks misuse and public backlash. The middle path — firmly regulated but widely accessible harm reduction tools — is where real progress lies. This includes decisive measures such as banning high-risk open-system vape devices prone to adulteration, while maintaining strict controls on other products. Regulation should target illicit and poorly regulated outlets through enhanced enforcement — without punishing law-abiding players who operate within compliance. Bakhtiar Talhah (second left) speaking on a HIV/AIDS advocacy programme. — Picture courtesy of Malaysian AIDS Foundation Enforcement initiatives like Ops Selamat Paru-Paru (Ops Selamat Papa), recently launched by the Ministry of Health, are an encouraging sign that the government recognises the urgency of the issue. However, enforcement has always been the Achilles' heel of public health in Malaysia. Raids, confiscations, and press conferences make headlines, but without sustained follow-through, the illicit market adapts and continues to thrive. For enforcement to succeed, it must be systematic, consistent, and paired with structural reforms: closing loopholes in licensing, disrupting illicit supply chains, and ensuring penalties are applied evenly. Otherwise, Ops Selamat Papa risks becoming another short-lived operation rather than a lasting pillar of harm reduction. Fiscal policy has a role too. In line with public health objectives, tax rates on vape products should be increased relative to cigarettes and heated tobacco sticks. A balanced tax framework can discourage uptake among youth, align with harm reduction goals for smokers, and generate revenue for health programmes. Equally important is the role of the private sector. I have seen firsthand how partnerships with foundations like Yayasan Sime Darby and corporate leaders such as Sunway Group have amplified impact in the HIV and health space. With strategic backing from the Ministry of Finance, the private sector can support innovation, financing, and delivery of sustainable harm reduction programmes. Religious authorities, particularly in Malaysia's Islamic context, have been instrumental in reframing harm reduction as a moral obligation to protect life. Fatwas and views that support methadone programmes and needle exchanges helped legitimise these interventions within the Muslim community. This synergy between faith and evidence is uniquely Malaysian — and powerful. This is why I founded Humanize Malaysia. We are a bridge — linking corporate actors, policymakers, civil society, and communities to drive sustainable change. Our mission is to humanise health, to put people — not ideology — at the centre of policy. The broader opportunity is this: harm reduction must evolve into a cornerstone of Malaysia's public health strategy — not just for HIV, but also for challenges like alcohol abuse, tobacco dependence, rising sugar consumption, and synthetic drug use. Every one of these issues shares a common truth: punitive responses fail. People do not need punishment — they need options, support, and dignity. Across the globe, countries that embraced harm reduction and reformed outdated drug laws are saving lives, reducing crime, and cutting costs. Japan's shift to heated tobacco products has already shown public health benefits and cost savings. In New Zealand, support for safer nicotine products helped halve adult smoking rates in just five years. Malaysia can, and must, be a leader in this space. We already know what works. Data-led policy. Bold political leadership. Corporate partnership. Community empowerment. Religious engagement. These are not new ideas — they are proven ingredients. But they require one thing above all: the courage to shift from criminalising to caring. Let us not wait for another epidemic to force our hand. Let's build on our past successes. Let's expand harm reduction and truly put health and humanity first. Let's humanise policy. Let's humanise health. * Bakhtiar Talhah is the CEO of Humanize Malaysia, trustee of the Malaysian AIDS Foundation, and former president of the Malaysian AIDS Council. ** This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
The Sun
2 days ago
- The Sun
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
HONG KONG SAR - Media OutReach Newswire - 30 July 2025 - The Greater Bay Area International Clinical Trial Institute of Hong Kong ('GBAICTI'), the Greater Bay Area International Clinical Trials Center of Shenzhen ('BAY TRIAL'), Immuno Cure BioTech ('Immuno Cure') in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding ('MOU') in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area ('GBA'), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen. GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform ('Platform') by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong. Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: 'The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.' Dr. LI Yichong, Director of BAY TRIAL, said: 'This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area's pharmaceutical and medical device industry.' Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy ('ART') can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host's immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure's ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART. Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People's Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People's Hospital, Tianjin Second People's Hospital, The Sixth People's Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center. Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: 'We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure's therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.' GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national 'Healthy China' strategic goals.
